Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579691 · ClinicalTrials.gov registry record · Phase 2
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
A Phase 2 study of Friedreich Ataxia, sponsored by Larimar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05579691 is a Phase 2 study of Friedreich Ataxia that has completed, run by Larimar Therapeutics. The registered enrollment target is 28 participants, below the 448-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05579691, a Phase 2 study of Friedreich Ataxia, has completed, sponsored by Larimar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL CTI-1601
Study Locations (1)
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2023-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05579691
The ClinicalTrials.gov registry entry for NCT05579691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (94% lower). The listed sponsor is Larimar Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Friedreich Ataxia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05579691 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05579691 about?
NCT05579691 is a clinical study titled "A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia". To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).
What is the current status of trial NCT05579691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2022-09-21. Estimated completion is 2023-12-04.
What conditions does trial NCT05579691 study?
This clinical trial studies the following conditions: Friedreich Ataxia.
What interventions are being tested in trial NCT05579691?
The interventions under investigation include: Placebo (OTHER), CTI-1601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05579691?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05579691 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Friedreich Ataxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
RECRUITING
-
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
RECRUITING · Phase 1
-
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
RECRUITING · Phase 1
-
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
RECRUITING
-
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.